List view / Grid view
Janssen Pharmaceuticals Inc.
The FDA has issued an Emergency Use Authorization for the single-dose Janssen COVID-19 Vaccine, making it the third COVID-19 vaccine available for use in the US.
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
Janssen have applied to the EMA to extend the use of esketamine to a short-term treatment for the rapid reduction of depressive symptoms in adults with MDD who are suicidal with the intent.
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.
14 July 2016 | By Victoria White, Digital Content Producer
If approved, chewable mebendazole will provide a treatment and prevention alternative for adults and children with soil-transmitted helminthiasis...
20 April 2016 | By Victoria White, Digital Content Producer
Data from a Phase I study of a preventive Ebola vaccine regimen suggest that the regimen was well-tolerated by healthy volunteers and immunogenic...
15 March 2016 | By Victoria White
A real-world study showed use of Invokana (canagliflozin) is associated with significantly greater improvements in blood glucose control compared to DPP-4 inhibitors...
14 October 2015 | By Victoria White
Janssen’s EPIDEPSO study was initiated to better understand the correlation between psychosocial comorbidities and psoriasis...
Oxford Vaccine Group initiates Phase 2 study of Ebola prime-boost vaccine regimen combining MVA-BN-Filo and Ad26.ZEBOV
15 July 2015 | By Victoria White
Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV...
Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
New clinical research programme launched for the prevention and treatment of blood clots in patients with cancer
29 May 2015 | By VIctoria White
Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer...